Status:
COMPLETED
Hydroxychloroquine in Giant Cell Arteritis
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Giant Cell Arteritis
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
Cortico-dependence is frequent in giant cell arteritis patients, and no drugs has proved its ability to prevent corticodependence. Hydrocychloroquine is a well tolerated immunomodulatory drug that may...
Eligibility Criteria
Inclusion
- giant celle arteritis with at least 3 ACR criteria including a disgnostic temporal artery biopsy
- corticosteroid treatment since less than 1 month
- age less than 85 years
- signed informed consent
Exclusion
- amaurosis fugax, loss of vision, acute lumb ischemia, angina pectoris or myocardium infarctus, mesenteric ischemia or other vascular complications related to GCA
- low life expectancy (\<2 years)
- corticosteroid treatment since more than 30 days whatever the dosage
- primary corticosteroid resistance defined by persistant symptoms despite prednisone for more than 15 days
- previous psychiatric troubles induced corticosteroids
- hydroxychloroquine contra-indicated
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00430807
Start Date
January 1 2002
End Date
December 1 2006
Last Update
October 6 2015
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital
Agen, France, 47923
2
Hospital
Albi, France, 81000
3
Hospital Auch
Auch, France, 32008
4
Hospital Avignon
Avignon, France, 84902